Joseph G. Pressey · Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Follow
Article1 min read·Published Nov 2026

Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Nov 2026 · 1 min read

In brief

In brief

This study investigates DUSP1 and DUSP6 phosphatases as therapeutic targets in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1. Inhibition of these enzymes suppresses tumor growth through JNK pathway modulation, offering a potential targeted treatment approach for these aggressive sarcomas.

Written by the GCMD Library team from the article.

Joseph G. Pressey

In neurofibromatosis type 1 (NF1) and in highly aggressive malignant peripheral nerve sheath tumors (MPNSTs), constitutively active RAS-GTP and increased MAPK signaling are important in tumorigenesis. Dual specificity phosphatases (DUSPs) are negative regulators of MAPK signaling that dephosphorylate p38, JNK, and ERK in different settings. Although often acting as tumor suppressors, DUSPs may als…

Statements in this article

  1. Constitutively active RAS-GTP and increased MAPK signaling are important in tumorigenesis in neurofibromatosis type 1 and malignant peripheral nerve sheath tumors.

    Established
  2. Dual specificity phosphatases are negative regulators of MAPK signaling that dephosphorylate p38, JNK, and ERK.

    Established
  3. Targeted inhibition of DUSP1 and DUSP6 suppresses malignant peripheral nerve sheath tumor growth via JNK.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.